| 时间 | 主题 | 主讲人 | |
| 8:30–8:40 | Opening speech on behalf of CSCO/CTONG | 吴一龙 |  |
主席(Chair): 刘晓晴 杨衿记 | |||
| 8:40–9:05 | A Randomized Controlled Trial of Erlotinib versus Gefitinib in Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations (CTONG0901)—Mini oral 16.13 | 杨衿记 | |
| Intercalating and Maintenance Use of Gefitinib plus Chemotherapy versus Chemotherapy Alone in Selected Advanced NSCLC(ISCAN, CTONG1102): A Phase III Study--- ORAL 32.06 | |||
| Randomized Trial of Gefitinib with and without Pemetrexed as First-Line Therapy in East-Asian Patients with Advanced NS NSCLC with EGFR Mutations?(JMIT)----Oral 17.02 | |||
| 9:05–9:25 | 解读：刘晓晴 | ||
| 9:25–9:40 | 讨论(Q & A) | 全体 | |
主席(Chair): 范 云 程 颖 | |||
| 9:40–10:05 | A randomized, phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non–small cell lung cancer (NSCLC): SWOG S0819----PLEN04:01 | 范 云 | |
EGFR IHC and?FISH Correlative Analyses (SQUIRE Trial): Necitumumab+Gemcitabine-Cisplatin vs Gemcitabine-Cisplatin in 1st-Line Squamous NSCLC-- Oral 32.05 | |||
| Bevacizumab 15mg/kg Plus Cisplatin-Pemetrexed (CP) vs CP in Malignant Pleural Mesothelioma (MPM): IFCT-GFPC-0701 MAPS Randomized Phase 3 Trial----Oral11.01 | |||
| 10:05–10:25 | 解读：程 颖 | ||
| 10:25–10:40 | 讨论(Q & A) | 全体 | |
| 10:40–10:55 | 茶歇(Tea?Break) | ||
主席(Chair): 胡 洁 伍 钢 | |||
| 10:55–11:20 | Erlotinib Combined with Chemotherapy versus Erlotinib Alone Treating Advanced Lung Adenocarcinoma with Brain Metastases (NCT01578668) -- Mini Oral 05.12 | 胡 洁 | |
| Prediction of Human Pharmacokinetics, Efficacious Dose and BBB Penetration of a Novel EGFR Inhibitor for Treating NSCLC with CNS Metastasis---MINI10.13 | |||
| Pooled Analysis of CNS Respond to Alectinib in two studies of pre-treated ALK+NSCLC--Oral 33.05 | |||
| 11:20–11:40 | 解读：伍 钢 | ||
| 11:40–12:00 | 讨论(Q & A) | 全体 | |
| 12:30-14:00 | 专家研讨会（会场一） | ||
| 专家研讨会（会场二） | |||
主席(Chair): 刘 喆 于世英 | |||
| 14:30-14:55 | Gefitinib/Chemotherapy vs Chemotherapy in EGFR Mutation-Positive NSCLC Resistant to First-Line Gefitinib: IMPRESS T790M Subgroup Analysis ---ORAL17.08 | 刘 喆 | |
| AZD9291 in Pre-Treated T790M Positive Advanced NSCLC: AURA2 Phase II Study ----MINI16.08 | |||
| Mechanisms of Acquired Resistance to AZD9291 in EGFR T790M Positive Lung Cancer--Oral 17.07 | |||
| 14:55-15:15 | 解读:于世英 | ||
| 15:15-15:30 | 讨论(Q & A) | 全体 | |
主席(Chair): 赵明芳 周 清 | |||
| 15:30-15:55 | Randomized Phase III Trial of Adjuvant Chemotherapy with or without Bevacizumab in Resected Non-Small Cell Lung Cancer (NSCLC):Results of E1505--Plen 04.03 | 周 清 | |
| Biomarkers for Efficacy in JO25567 Study Evaluating | |||
| Erlotinib plus Bevacizumab versus Erlotinib in Advanced NSCLC with EGFR Mutation --Oral17.03 | |||
| NEJ016:PhaseⅡ?Study of CBDCA and Weekly PTX plus BEV Followed by BEV for Highly Selected Elderly Non-Squamous NSCLC Patients--?MINI15.02 | |||
| 15:50-16:10 | 解读:赵明芳 | 全体 | |
| 16:10-16:25 | 讨论(Q & A) | ||
| 16:25-16:40 | 茶歇 | ||
主席(Chair): 张绪超 崔久嵬 | |||
| 16:40-17:05 | Molecular Tumor Board(MTB) in non-small cell lung cancers(NSCLC) to optimize targeted therapies: 4 Years’ Experience at Gustave Roussy---- Oral 06.05 | 崔久嵬 | |
| Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer----Oral 38.02 | |||
| Quantification of Mutant Alleles in Circulating Tumor DNA from Advanced Non-Small Cell Lung Cancer ---ORAL16.06 | |||
| 17:05-17:25 | 解读：张绪超 | ||
| 17:25-17:40 | 讨论(Q & A) | 全体 | |
Keynote speech主持人： 吴一龙 | |||
| 17:40-18:00 | 2015肺癌病理分类与临床实践 | 钟文昭 | |
| 18:00-18:10 | 总结 | 吴一龙 | |
| 18:30-20:00 | 晚餐 |